Head to Head Contrast: Valeritas (OTCMKTS:VLRXQ) vs. IceCure Medical (NASDAQ:ICCM)

IceCure Medical (NASDAQ:ICCM) and Valeritas (OTCMKTS:VLRXQ) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Valuation & Earnings

This table compares IceCure Medical and Valeritas”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38 million	3.04	-$15.06 million	($7.21)	-0.42
Valeritas	N/A	N/A	N/A	N/A	N/A

Valeritas has lower revenue, but higher earnings than IceCure Medical.

Institutional & Insider Ownership

0.6% of IceCure Medical shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Comparatively, 1.0% of Valeritas shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares IceCure Medical and Valeritas’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-427.67%	-188.60%	-119.80%
Valeritas	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings for IceCure Medical and Valeritas, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	1	1	3	0	2.40
Valeritas	0	0	0	0	0.00

IceCure Medical presently has a consensus target price of $52.50, indicating a potential upside of 1,650.00%. Given IceCure Medical’s stronger consensus rating and higher probable upside, research analysts clearly believe IceCure Medical is more favorable than Valeritas.

Summary

IceCure Medical beats Valeritas on 6 of the 9 factors compared between the two stocks.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

About Valeritas

Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.